Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Provides SEC Reporting UpdateAugust 10, 2021

2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate. Amended and Restated Form 10-K Includes Complete Restated Financial Statements and Currently Dated, Unqualified Audit Report.

Texas Adds Endari to Latest Preferred Drug ListAugust 02, 2021

Emmaus Life Sciences, Inc. (OTC: EMMA) announced today that Endari has been included on the Preferred Drug List published on July 29, 2021, by Texas Health and Human Services (THHS).

Emmaus Life Sciences Provides Interim Sales InformationJuly 22, 2021

Emmaus Life Sciences, Inc. announced today preliminary sales results for the six months ended June 30, 2021.

Emmaus Life Sciences Announces Submission of Endari Marketing Authorization Application in KuwaitJuly 15, 2021

Emmaus Life Sciences, Inc. (OTC: EMMA) announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to SwissmedicJune 15, 2021

Emmaus Life Sciences, Inc announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus’ application for Marketing Authorization (MA) for Endari® in Switzerland.